Damtix 200 mg/40 mg spot-on solution for dogs up to 4 kg

Authorised

- Permethrin (40:60)
- Imidacloprid

Product identification

Medicine name:
Damtix 200 mg/40 mg spot-on solution for dogs up to 4 kg

Active substance:
Permethrin (40:60)

Imidacloprid

Target species:
Dog

Route of administration:
Spot-on use

Product details

Active substance and strength:
Permethrin (40:60)
200.00 milligram(s) / 1.00 Pipette

Imidacloprid

40.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:
Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP53AC54

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Greece

Available in:
Greece

Package description:
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 1 pipette
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 3 pipettes
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 4 pipettes
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 6 pipettes
White polypropylene pipette closed with a polyethylene (HDPE) cap. Each pipette is packed in a polyethylene terephthalate/aluminium/low density polyethylene triplex bag. 1 ml pipette containing 0.4 ml of solution Box containing 10 pipettes

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
KRKA tovarna zdravil d.d. Novo mesto

Marketing authorisation date:
21/06/2022

Manufacturing sites for batch release:
KRKA tovarna zdravil d.d. Novo mesto

Responsible authority:
National Organization For Medicines

Authorisation number:
67541/22-06-2022/K-0248901

Date of authorisation status change:
21/06/2022

Reference member state:
Ireland

Procedure number:
IE/V/0663/001

Concerned member states:
Finland France Germany Greece Italy Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

Combined File of all Documents